Jin Zhang M.D., Ph.D

Jin Zhang M.D., Ph.D is editor at The Pharmaceutical Consultant.


Bispecific Antibodies in China

Jin Zhang provides an overview of China's major bispecific antibody developers.

The TKI Lung Cancer Market in China

Tyrosine-kinase inhibitors (TKIs) are gradually becoming the most popular option for lung cancer treatment in China. Jin Zhang reports.

China Expedites Price Reduction of Anticancer Drugs

In an attempt to reduce high drug prices and improve its medical insurance coverage, China has initiated a series of new moves, including the recent zero import tax on a range of anticancer drugs. Jin Zhang reports.